
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INSILICO MEDICINE

InSilico Medicine Cayman TopCo
英矽智能

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3696)

VOLUNTARY ANNOUNCEMENT

INSILICO MEDICINE AND SK BIOPHARMACEUTICALS ACHIEVED AI-POWERED R&D COLLABORATION WORTH UP TO USD2.5 BILLION FOR NEUROIMMUNE DISORDERS

This announcement is made by InSilico Medicine Cayman TopCo (the "**Company**", together with its subsidiaries, the "**Group**" or "**Insilico Medicine**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that Insilico Medicine and SK Biopharmaceuticals Co., Ltd. ("**SK Biopharmaceuticals**") have entered into a research and development collaboration to discover AI-enabled innovative drug candidates in the neuroimmune area of the central nervous system (the "**Collaboration**").

In this Collaboration, Insilico Medicine will leverage its proprietary Pharma.AI platform, which spans target validation, generative chemistry, and molecule optimization, together with its preclinical drug discovery expertise to discover, design, and optimize novel candidates for neuroimmune indications. SK Biopharmaceuticals will contribute its extensive development and clinical capabilities in neuroimmune disorders, steering the late-stage development and commercialization of all resulting programs.

Under the terms of the relevant agreement, Insilico Medicine will be eligible to receive up to USD18 million in upfront and near-term milestone payments. The total potential deal value exceeds USD2.5 billion, including development, regulatory, and commercial milestone payments, as well as single-digit royalties on net sales upon commercialization of products.

About SK Biopharmaceuticals

SK Biopharmaceuticals is a global biotech company focused on the research, development, and commercialization of innovative therapies for central nervous system (CNS) disorders and beyond. The company achieved a historic milestone as the first Korean pharmaceutical company to independently develop and commercialize a novel drug in the United States with XCOPRI® (cenobamate), an innovative treatment for epilepsy.

Through its U.S. subsidiary, SK Life Science, Inc., SK Biopharmaceuticals has established a direct commercial platform in the United States while expanding its global footprint through strategic partnerships across Europe, Latin America, the Middle East, North Africa, and Asia. The company continues to broaden patient access and strengthen its long-term growth potential through ongoing label and geographic expansion efforts.

Building on its commercial success, SK Biopharmaceuticals is advancing a diversified pipeline and investing in next-generation growth drivers, including radiopharmaceutical therapies (RPTs) and targeted protein degradation (TPD). Through open innovation and collaborations with leading global institutions and companies, the company continues to expand its innovation ecosystem and R&D capabilities.

SK Biopharmaceuticals is also leveraging AI and digital technologies across the drug discovery, development, and treatment continuum to enhance patient outcomes and experiences. By integrating scientific innovation with digital healthcare solutions, the company aims to build a patient-centered healthcare ecosystem and realize its vision of becoming a balanced Big Biotech.

About Insilico Medicine

Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend health longevity to people on the planet. The Company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.

By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico Medicine is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico Medicine extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com.

Forward Looking Statement

There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By order of the Board
InSilico Medicine Cayman TopCo
Mr. Aleksandrs Zavoronkovs, Ph.D.
Chairman, Executive Director, CEO and CBO

Hong Kong, June 22, 2026

As at the date of this announcement, the board of directors of the Company comprises Mr. Aleksandrs Zavoronkovs, Ph.D. and Mr. Feng Ren, Ph.D. as executive directors; Mr. Kan Chen, Ph.D., Mr. Chuen Yan Leung, Ph.D., and Mr. Long Shi as non-executive directors; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman Kyrychynskyi as independent non-executive directors.